The Biopsy Devices Market is witnessing transformative growth, fueled by technological advancements, the rising prevalence of cancer, and an increasing demand for minimally invasive procedures. According to Market Research Future (MRFR), the market was valued at USD 2.81 billion in 2024 and is projected to reach USD 5.182 billion by 2035, growing at a CAGR of 5.72% from 2025 to 2035. This growth underscores the increasing focus on precision diagnostics and early disease detection across healthcare systems worldwide.
Key Market Drivers
The growth of the biopsy devices market is underpinned by several critical factors:
Rising Incidence of Cancer: Cancer remains one of the leading causes of mortality globally, propelling demand for accurate diagnostic tools, including needle biopsies, core needle biopsies (CNB), and vacuum-assisted biopsy (VAB) devices.
Growing Geriatric Population: Aging populations in developed regions increase the need for diagnostic procedures, making biopsy devices essential for timely and accurate detection.
Technological Advancements: Innovations such as AI-assisted imaging, robotic biopsy systems, and minimally invasive devices are enhancing procedural accuracy and reducing patient discomfort.
Emphasis on Early Detection: Preventive healthcare initiatives and early screening programs are driving adoption of advanced biopsy devices, particularly in breast, prostate, and lung cancer diagnostics.
Market Segmentation Insights
By Product Type
Biopsy Guns: Dominant in the market due to efficiency and widespread clinical use.
Biopsy Guidance Systems: Fastest-growing segment, fueled by imaging advancements and robotic-assisted procedures.
Biopsy Needles: Includes FNAB, CNB, and VAB devices, evolving with specialized applications.
Biopsy Forceps & Localization Wires: Support specific procedural needs in minimally invasive interventions.
By Application
Breast Biopsy: Holds the largest share, reflecting high breast cancer prevalence and early detection programs.
Prostate Biopsy: Fastest-growing, driven by enhanced diagnostic techniques and rising prostate cancer cases.
Liver, Lung, and Gynecological Biopsies: Emerging applications with potential due to technological improvements and screening initiatives.
By Guidance Technique
Ultrasound-Guided Biopsy: Most widely used, offering real-time imaging and cost-effectiveness.
MRI-Guided Biopsy: Fastest-growing, benefiting from non-invasive imaging and AI integration.
Stereotactic & CT-Guided Biopsies: Complement precision targeting in complex cases.
By End User
Hospitals & Clinics: Largest end-user segment, leveraging robust infrastructure for diverse biopsy procedures.
Diagnostic & Imaging Centers: Fastest-growing, emphasizing advanced, non-invasive techniques for patient-centric care.
Academic & Research Institutes: Increasingly adopting innovative biopsy solutions for research and clinical trials.
Regional Insights
Explore the full report here:
North America: Leading the market with 45% share, driven by technological adoption, regulatory support from the FDA, and strong R&D investments.
Europe: Holds 30% share, with key markets including Germany, France, and the UK. Regulatory frameworks and early cancer detection initiatives boost growth.
Asia-Pacific: Rapidly growing (20% share), propelled by healthcare infrastructure expansion, rising cancer awareness, and increased investment in medical technology.
Middle East & Africa: Emerging market (5% share) with opportunities in expanding diagnostic services and healthcare investments.
Key Market Trends
Integration of AI and Digital Technologies: Companies like Hologic, Inc. and Medtronic plc are leveraging AI-driven imaging and telehealth capabilities to enhance diagnostic accuracy.
Minimally Invasive Focus: Adoption of fine needle aspiration, vacuum-assisted biopsies, and endoscopic ultrasound-guided techniques is rising.
Strategic Partnerships & Expansion: Collaborations and facility expansions, such as BD’s manufacturing growth in the US, are enhancing market penetration and supply chain efficiency.
Sustainability & Biodegradable Devices: Innovative solutions are addressing environmental concerns while improving patient safety.
Competitive Landscape
The Biopsy Devices Market is moderately fragmented but driven by innovation. Key players include:
Becton Dickinson and Company (US)
Boston Scientific Corporation (US)
Medtronic plc (IE)
Hologic, Inc. (US)
Thermo Fisher Scientific Inc. (US)
Siemens Healthineers AG (DE)
Abbott Laboratories (US)
Cook Medical Incorporated (US)
Johnson & Johnson (US)
Recent strategic moves include:
Hologic, Inc.: Launched AI-integrated biopsy devices enhancing tissue sampling precision (Aug 2025).
Medtronic plc: Partnered with telehealth providers for remote biopsy monitoring (Sep 2025).
Becton Dickinson: Expanded US manufacturing to meet rising global demand (July 2025).
Future Outlook
The Biopsy Devices Market is poised for sustained growth through 2035, driven by:
AI-integrated biopsy systems for improved diagnostic outcomes.
Expansion of telehealth-enabled biopsy consultations.
Development of biodegradable and patient-friendly devices aligning with sustainability goals.
As healthcare continues to prioritize precision diagnostics and patient-centric solutions, the biopsy devices market will remain a critical segment in modern medical technology. Companies focusing on innovation, digitalization, and minimally invasive procedures are expected to lead the next phase of growth.
Conclusion
The global Biopsy Devices Market represents a dynamic and evolving landscape characterized by technological innovation, growing disease prevalence, and an emphasis on patient-centric care. With a projected CAGR of 5.72% and expanding applications across breast, prostate, liver, and lung diagnostics, the market offers significant opportunities for manufacturers, healthcare providers, and investors alike.
